Clinical trials: Chloroquine
Vivax Malaria
Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
For the treatment of P.vivax the standard treatment is chloroquine. There is a growing body of evidence suggesting that pregnant women may require different doses of drugs, including antimalarials due to the physiological changes…
- Trial name
- KCP (NCT01546961)
- Testing
- Chloroquine
- Where
- Thailand
- Volunteers
- 49 people
- Sponsor
- University of Oxford
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia
The primary objective is to confirm the hypothesis that azithromycin (optimal dose once daily for three days) plus chloroquine is non-inferior to sulfadoxine-pyrimethamine plus chloroquine for the treatment of uncomplicated…
- Trial name
- NCT00084240
- Testing
- Azithromycin/Chloroquine, Sulfadoxine-Pyrimethamine/Chloroquine
- Volunteers
- 32 people
- Sponsor
- Pfizer
COVID-19 Pneumonia
Chloroquine + Losartan Compared to Chloroquine Alone for the Treatment of COVID-19 Pneumonia
Study design Phase 2, double blinded, single-center, 1:1 randomized clinical trial of Chloroquine vs Chloroquine/losartan for the treatment of SARS-CoV-2 pneumonia in non-critically ill subjects
- Trial name
- NCT04428268
- Testing
- Chloroquine Phosphate Tablets
- Where
- Mexico
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Malaria, Falciparum Malaria
ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan
Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast.
- Conditions
- Malaria, Falciparum Malaria, Vivax Malaria
- Trial name
- NCT00158548
- Testing
- SP, chloroquine, amodiaquine, primaquine, artesunate
- Where
- Pakistan
- Volunteers
- 650 people
- Sponsor
- London School of Hygiene and Tropical Medicine
COVID-19
Chloroquine for Mild Symptomatic and Asymptomatic COVID-19
19 COVID (Coronavirus disease 2019 ) is a deadly viral disease that has been spreading around the world for several months, and is caused by a CORONA family virus (COVID-19).
- Trial name
- NCT04333628
- Testing
- chloroquine, standard care
- Where
- Israel
- Volunteers
- 5 people
- Sponsor
- HaEmek Medical Center, Israel
Malaria, Vivax
Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria
This is a prospective, double-blind, double-dummy, multicenter, comparative study. A total of 300 subjects will be randomized to treatment on Day 1, of which a minimum of 50 female subjects must be enrolled that display moderate…
- Trial name
- NCT02216123
- Testing
- Tafenoquine, Chloroquine, Primaquine
- Where
- 10 sites in Brazil, Colombia and 4 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
COVID-19
Interferon Beta 1a in Hospitalized COVID-19 Patients
The present study is a randomized, double-blind, placebo-controlled, clinical trial, with the approval of the ethics committee will be conducted on patients who have a positive test confirming COVID-19 in Loghman Hakim Medical…
- Trial name
- IB1aIC (NCT04350671)
- Testing
- Interferon Beta-1A, Lopinavir / Ritonavir, Single Dose of Hydroxychloroquine
- Where
- Iran
- Volunteers
- 40 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Malaria, Falciparum
Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa
The primary objective is to confirm the hypothesis that azithromycin used in combination with chloroquine is non-inferior to artemether- Lumefantrine for the treatment of symptomatic, uncomplicated malaria due to P.
- Trial name
- NCT00677833
- Testing
- Azithromycin plus Chloroquine, Artemether-lumefantrine
- Where
- 7 sites in Burkina Faso, Côte d’Ivoire and 3 more
- Volunteers
- 361 people
- Sponsor
- Pfizer
HIV Infections
Evaluation of the Efficacy of Hydroxychloroquine in Decreasing Immune Activation in Asymptomatic HIV-infected Patients
The purpose of this pilot study is to find out if taking hydroxychloroquine will decrease immune activation (stimulation of the body's defence system) in people with early HIV infection.
- Trial name
- HCQ-01 (NCT01067417)
- Testing
- Hydroxychloroquine
- Volunteers
- 83 people
- Sponsor
- Medical Research Council
COVID-19
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
There is a pandemic in the world by COVID-19. Currently, the pharmacological curative or prophylactic treatments for this infection are not known.
- Trial name
- PREPCOV (NCT04481633)
- Testing
- COVID 19 serology, COVID 19 Self-Questionnaire
- Where
- 12 sites in France
- Volunteers
- 547 people
- Sponsor
- University Hospital, Toulouse
Covid-19 Infection, Rheumatoid Arthritis
IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT
This study aims to evaluate the experience of Alberta patients with inflammatory arthritis who participate in the the RAPPORT-ONTRAAC registry during the COVID-19 pandemic, specifically comparing the experience of those taking…
- Conditions
- Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis, Hydroxychloroquine
- Trial name
- IMPACT (NCT04347798)
- Testing
- Hydroxychloroquine/Chloroquine
- Where
- Canada
- Volunteers
- 773 people
- Sponsor
- University of Alberta
Malaria
Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis
This is an open label, Phase 2 study with controlled human malaria infection (CHMI). Twenty three subjects will be enrolled into 2 groups (15 subjects in the Chloroquine-Azithromycin [CQ/AZ] Intervention Group, and 8 subjects in…
- Trial name
- NCT03278808
- Testing
- Chloroquine-Azithromycin (CQ/AZ), Chloroquine (CQ), atovaquone-proguanil (Malarone®)
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Metabolic Syndrome X, Overweight
Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)
Metabolic syndrome consists of a group of co-occuring conditions that increase an individual's risk of developing heart disease, stroke, and diabetes.
- Conditions
- Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias
- Trial name
- ARCH-MS (NCT00455403)
- Testing
- Chloroquine
- Where
- United States
- Volunteers
- 357 people
- Sponsor
- Washington University School of Medicine
P Vivax, Malaria, Vivax
Efficacy of 3 Regimens of Chloroquine and Primaquine for Treatment of P. Vivax Malaria, Cruzeiro do Sul, Acre, Brazil
We plan to assess the efficacy of 3 different regimens of chloroquine and primaquine for the treatment of P. vivax infections in Cruzeiro do Sul, Acre, Brazil.
- Trial name
- NCT03610399
- Testing
- Primaquine
- Where
- Brazil
- Volunteers
- 257 people
- Sponsor
- Centers for Disease Control and Prevention
Glioblastoma
Chloroquine for Glioblastoma.
Adjuvant chloroquine to the conventional treatment for glioblastoma; A randomized, single-blind, placebo-controlled, phase I/II trial.
- Trial name
- NCT04772846
- Testing
- Oral tablet
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Egyptian Medical Syndicate
Plasmodium Falciparum Infection
Chloroquine Alone or in Combination for Malaria in Children in Malawi
Malaria is a sickness caused by a germ that can get into a person's body when a mosquito bites them. It can cause fever, headache, body aches and weakness. It can even cause death, especially in children.
- Trial name
- NCT00379821
- Testing
- Atovaquone-proguanil, Artesunate, Azithromycin
- Where
- Malawi
- Volunteers
- 640 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2
In December 2019, the Municipal Health Committee of Wuhan, China, identified an outbreak of viral pneumonia of unknown cause. This new coronavirus was called SARS-CoV-2 and the disease caused by that virus, COVID-19.
- Trial name
- CloroCOVID19 (NCT04323527)
- Testing
- Chloroquine diphosphate
- Where
- Brazil
- Volunteers
- 278 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Malaria, Falciparum
Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau
This study will evaluate the efficacy of treatment with artemether-lumefantrine as compared to chloroquine in the dose of 50 mg/kg for treatment of malaria in children in Guinea-Bissau.
- Trial name
- NCT00426439
- Testing
- Chloroquine, Artemether-lumefantrine (Coartem)
- Where
- Guinea-Bissau
- Volunteers
- 300 people
- Sponsor
- Bandim Health Project
Malaria Prophylaxis
A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects
Estimate the relative bioavailability of co-administered azithromycin microsphere (2000 mg) and the chloroquine (620 mg CQ base) test formulation compared to co-administered immediate release individual tablets of azithromycin…
- Trial name
- AZCQ (NCT01100060)
- Testing
- azithromycin (AZ) microsphere, test chloroquine (CQ) formulation, azithromycin (AZ)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Pfizer